Stemline Therapeutics Inc (NASDAQ:STML) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.18, Bloomberg Earnings reports. Stemline Therapeutics had a negative net margin of 5,162.64% and a negative return on equity of 71.60%. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million.

Shares of Stemline Therapeutics (STML) traded down 4.68% during mid-day trading on Wednesday, hitting $8.15. The stock had a trading volume of 128,485 shares. The stock has a 50 day moving average price of $9.34 and a 200-day moving average price of $8.61. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $14.60. The company’s market cap is $190.51 million.

Several analysts have commented on the company. HC Wainwright set a $34.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday. ValuEngine lowered Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. Finally, Wedbush raised their price objective on Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $29.17.

TRADEMARK VIOLATION NOTICE: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Earnings History for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with's FREE daily email newsletter.